open access
Vol 52, No 2 (2021)
Editorial
Submitted: 2021-03-22
Accepted: 2021-03-22
Get Citation
TP53 mutations in chronic lymphocytic leukemia
Tadeusz Robak1
DOI: 10.5603/AHP.2021.0012
·
Acta Haematol Pol 2021;52(2):75-76.
Affiliations- Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland
open access
Vol 52, No 2 (2021)
EDITORIAL
Submitted: 2021-03-22
Accepted: 2021-03-22
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
TP53 mutations in chronic lymphocytic leukemia
Journal
Issue
Article type
Editorial
Pages
75-76
Page views
258
Article views/downloads
362
DOI
10.5603/AHP.2021.0012
Bibliographic record
Acta Haematol Pol 2021;52(2):75-76.
Authors
Tadeusz Robak
References (10)- Te Raa GD, Kater AP. TP53 dysfunction in CLL: implications for prognosis and treatment. Best Pract Res Clin Haematol. 2016; 29(1): 90–99.
- Eichhorst B, Robak T, Montserrat E, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(1): 23–33.
- Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia. 2009; 23(1): 117–124.
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016; 17(6): 779–790.
- Malcikova J, Pavlova S, Kozubik KS, et al. TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemia. Hum Mutat. 2014; 35(6): 663–671.
- Pepek M, Pula B, Machnicki MM, et al. Results of Polish Adult Leukemia Study Group (PALG) project assessing TP53 mutations with next-generation sequencing technology in relapsed and refractory chronic lymphocytic leukemia patients — 18 months update. Acta Haematol Pol. 2021; 52(2): XX–XX.
- Rigolin GM, Saccenti E, Bassi C, et al. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. J Hematol Oncol. 2016; 9(1): 88.
- Malcikova J, Tausch E, Rossi D, et al. European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia. 2018; 32(5): 1070–1080.
- Kantorova B, Malcikova J, Smardova J, et al. TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods. Tumour Biol. 2015; 36(5): 3371–3380.
- Nadeu F, Delgado J, Royo C, et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016; 127(17): 2122–2130.